Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study
Changxia Shao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wei Zhou(Broad Institute), Fan Jin(Second Affiliated Hospital of Xi'an Jiaotong University), Elisha J. Dettman(Eutropics Pharmaceuticals (United States)), Liam C. Lee(Center for Cancer Research), Yixin Ren(Johns Hopkins University), Heng Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cai Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alexander Gozman(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 1
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Rapidly in Situ Forming Biodegradable Robust Hydrogels by Combining Stereocomplexation and Photopolymerization
|Journal of the American Chemical Society|2007|156
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
|Journal of Thoracic Oncology|2016|156